Response to Treatment in a Prospective Cohort of Patients with Large Ulcerated Lesions Suspected to Be Buruli Ulcer (Mycobacterium ulcerans Disease)

Background The World Health Organization (WHO) advises treatment of Mycobacterium ulcerans disease, also called “Buruli ulcer” (BU), with a combination of the antibiotics rifampicin and streptomycin (R+S), whether followed by surgery or not. In endemic areas, a clinical case definition is recommended. We evaluated the effectiveness of this strategy in a series of patients with large ulcers of ≥10 cm in longest diameter in a rural health zone of the Democratic Republic of Congo (DRC). Methods A cohort of 92 patients with large ulcerated lesions suspected to be BU was enrolled between October 2006 and September 2007 and treated according to WHO recommendations. The following microbiologic data were obtained: Ziehl-Neelsen (ZN) stained smear, culture and PCR. Histopathology was performed on a sub-sample. Directly observed treatment with R+S was administered daily for 12 weeks and surgery was performed after 4 weeks. Patients were followed up for two years after treatment. Findings Out of 92 treated patients, 61 tested positive for M. ulcerans by PCR. PCR negative patients had better clinical improvement than PCR positive patients after 4 weeks of antibiotics (54.8% versus 14.8%). For PCR positive patients, the outcome after 4 weeks of antibiotic treatment was related to the ZN positivity at the start. Deterioration of the ulcers was observed in 87.8% (36/41) of the ZN positive and in 12.2% (5/41) of the ZN negative patients. Deterioration due to paradoxical reaction seemed unlikely. After surgery and an additional 8 weeks of antibiotics, 98.4% of PCR positive patients and 83.3% of PCR negative patients were considered cured. The overall recurrence rate was very low (1.1%). Interpretation Positive predictive value of the WHO clinical case definition was low. Low relapse rate confirms the efficacy of antibiotics. However, the need for and the best time for surgery for large Buruli ulcers requires clarification. We recommend confirmation by ZN stain at the rural health centers, since surgical intervention without delay may be necessary on the ZN positive cases to avoid progression of the disease. PCR negative patients were most likely not BU cases. Correct diagnosis and specific management of these non-BU ulcers cases are urgently needed.

[1]  W. Meyers,et al.  Distribution of Mycobacterium ulcerans infections in Zaire, including the report of new foci. , 1974, Annales de la Societe belge de medecine tropicale.

[2]  D. O’Brien,et al.  “Paradoxical” immune‐mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure , 2009, The Medical journal of Australia.

[3]  P. Itin,et al.  Development of Highly Organized Lymphoid Structures in Buruli Ulcer Lesions after Treatment with Rifampicin and Streptomycin , 2007, PLoS neglected tropical diseases.

[4]  Buruli ulcer: progress report, 2004-2008. , 2008, Releve epidemiologique hebdomadaire.

[5]  F. Portaels,et al.  Buruli ulcer: an historical overview with updating to 2005 , 2005 .

[6]  J. Aguiar,et al.  L'ulcère de Buruli: Attention aux atteintes osseuses ! A propos de 33 cas observés au Benin , 2000 .

[7]  G. Bretzel,et al.  Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial , 2010, The Lancet.

[8]  J. Guarner,et al.  Analysis of an IS2404-Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic , 2003, Journal of Clinical Microbiology.

[9]  F. Portaels,et al.  Association of HIV infection and Mycobacterium ulcerans disease in Benin , 2008, AIDS.

[10]  F. Portaels,et al.  Buruli Ulcer Lesions in HIV-Positive Patient , 2010, Emerging infectious diseases.

[11]  R. Spiegel,et al.  A pilot study of treatment of Buruli ulcer with rifampin and dapsone. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[12]  G. Pluschke,et al.  Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases , 2008, Tropical medicine & international health : TM & IH.

[13]  C. Horsfield,et al.  Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans , 2005, Antimicrobial Agents and Chemotherapy.

[14]  Y. Nakazawa,et al.  New Foci of Buruli Ulcer, Angola and Democratic Republic of Congo , 2008, Emerging infectious diseases.

[15]  F. Portaels,et al.  Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. , 2006, The American journal of tropical medicine and hygiene.

[16]  M. Sarkar,et al.  Buruli ulcer: a systemic disease. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Hayman Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. , 1993, Journal of clinical pathology.

[18]  J. Grosset,et al.  Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease) , 2007, Antimicrobial Agents and Chemotherapy.

[19]  C. Holcombe,et al.  Buruli ulcer. , 2015, Journal of the Indian Medical Association.

[20]  D. Connor,et al.  Buruli Ulceration. A Clinicopathologic Study of 38 Ugandans with Mycobacterium ulcerans Ulceration. , 1966 .

[21]  K. Kibadi Ulcère à Mycobacterium ulcerans : Prise en charge chirurgicale dans 102 observations en République Démocratique du Congo , 2005 .

[22]  B. Ross,et al.  Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection , 1997, Journal of clinical microbiology.

[23]  J. Guarner,et al.  Histopathologic Features of Mycobacterium ulcerans Infection , 2003, Emerging infectious diseases.

[24]  F. Portaels,et al.  Mycobacterium ulcerans Disease (Buruli Ulcer) in Rural Hospital, Southern Benin, 1997–2001 , 2004, Emerging infectious diseases.

[25]  Cécile Uwizeye,et al.  Primary Culture of Mycobacterium ulcerans from Human Tissue Specimens after Storage in Semisolid Transport Medium , 2007, Journal of Clinical Microbiology.

[26]  O. Dodge MYCOBACTERIAL SKIN ULCERS IN UGANDA: HISTOPATHOLOGICAL AND EXPERIMENTAL ASPECTS. , 1964, The Journal of pathology and bacteriology.

[27]  K. Kibadi [Mycobacterium ulcerans disease (Buruli ulcer): surgical treatment of 102 cases in the Democratic Republic of Congo]. , 2005, Medecine tropicale : revue du Corps de sante colonial.

[28]  Paul D. R. Johnson Should antibiotics be given for Buruli ulcer? , 2010, The Lancet.